Journal Title：Oncotargets And Therapy

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents

-Novel therapeutic regimens for improved benefit and/or decreased side effects

-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.

-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.

-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.

-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Single nucleotide polymorphism (SNP) studies will not be considered.

OncoTargets and Therapy 是一本國(guó)際同行評(píng)審期刊，專注于癌癥研究的分子方面，即所有類型癌癥的分子診斷和靶向分子或精準(zhǔn)治療。

該期刊的特點(diǎn)是快速報(bào)道高質(zhì)量的原創(chuàng)研究、基礎(chǔ)科學(xué)、評(píng)論和評(píng)估、專家意見和評(píng)論，為癌癥或癌癥亞型提供新的見解。

該期刊涵蓋的具體主題包括：

-新的治療靶點(diǎn)和創(chuàng)新藥物

-用于提高療效和/或減少副作用的新型治療方案

-早期臨床試驗(yàn)

向 OncoTargets and Therapy 投稿時(shí)的進(jìn)一步考慮：

-包含體內(nèi)動(dòng)物模型數(shù)據(jù)的研究將得到優(yōu)先考慮。

-組織微陣列分析將不予考慮，除非它們得到涉及多個(gè)細(xì)胞的綜合生物學(xué)研究的支持行。

-只有通過全面的體外數(shù)據(jù)和人體組織樣本分析進(jìn)行驗(yàn)證后，才會(huì)考慮生物標(biāo)志物關(guān)聯(lián)研究。

-利用公開數(shù)據(jù)（例如 GWAS/TCGA/GEO 等）的研究應(yīng)增加有關(guān)特定疾病或相關(guān)表型的知識(shí)體系，并且必須使用作者自己的數(shù)據(jù)通過在獨(dú)立樣本集中復(fù)制和功能跟蹤進(jìn)行驗(yàn)證。

-生物信息學(xué)研究必須使用作者自己的數(shù)據(jù)通過在獨(dú)立樣本集中復(fù)制和功能跟蹤進(jìn)行驗(yàn)證。

-單核苷酸多態(tài)性 (SNP) 研究將不予考慮。

Oncotargets And Therapy創(chuàng)刊于2008年，由Dove Medical Press Ltd.出版商出版，收稿方向涵蓋BIOTECHNOLOGY & APPLIED MICROBIOLOGY - ONCOLOGY全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細(xì)分領(lǐng)域中專業(yè)影響力一般，過審相對(duì)較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機(jī)率較高。平均審稿速度 較慢,6-12周 ，影響因子指數(shù)2.7，該期刊近期被列入國(guó)際期刊預(yù)警名單，請(qǐng)廣大學(xué)者慎重選擇。